Agilent Technologies (A) reported $1.86 billion in revenue for the quarter ended October 2025, representing a year-over-year increase of 9.4%. EPS of $1.59 for the same period compares to $1.46 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $1.83 billion, representing a surprise of +1.49%. The company has not delivered EPS surprise, with the consensus EPS estimate being $1.59.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Agilent performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Revenue- Applied Markets: $351 million versus the four-analyst average estimate of $354.81 million.
- Net Revenue- Agilent Crosslab Group: $755 million versus the four-analyst average estimate of $750.83 million. The reported number represents a year-over-year change of +77.2%.
- Net Revenue- Life Sciences and Diagnostics Markets Segment: $755 million versus the four-analyst average estimate of $728.07 million. The reported number represents a year-over-year change of -9.4%.
- Revenue by End Markets- Environmental and Forensics: $180 million compared to the $180.82 million average estimate based on two analysts. The reported number represents a change of +9.8% year over year.
- Revenue by End Markets- Academia and Government: $136 million versus the two-analyst average estimate of $158.45 million. The reported number represents a year-over-year change of -9.3%.
- Revenue by End Markets- Pharmaceutical: $690 million compared to the $645.74 million average estimate based on two analysts. The reported number represents a change of +16% year over year.
- Revenue by End Markets- Food: $165 million compared to the $164.74 million average estimate based on two analysts. The reported number represents a change of +8.6% year over year.
- Revenue by End Markets- Chemical and advanced materials: $414 million versus $410.16 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +7.5% change.
- Revenue by End Markets- Diagnostics and Clinical: $276 million versus the two-analyst average estimate of $266.56 million. The reported number represents a year-over-year change of +8.2%.
View all Key Company Metrics for Agilent here>>>
Shares of Agilent have returned +2.2% over the past month versus the Zacks S&P 500 composite's -1.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Agilent Technologies, Inc. (A): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
